Lantheus (NASDAQ:LNTH) Rating Lowered to “Hold” at Leerink Partners

Lantheus (NASDAQ:LNTH) was downgraded by stock analysts at Leerink Partners from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. William Blair set a $102.50 price objective on shares of Lantheus in a research report on Monday. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Weiss Ratings upgraded Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday. Citizens Jmp reissued a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a report on Monday, June 29th. Finally, CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday. Five investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Lantheus currently has a consensus rating of “Hold” and an average target price of $108.11.

Lantheus Price Performance

Shares of LNTH opened at $101.11 on Monday. The company’s 50-day moving average is $103.98 and its 200-day moving average is $87.37. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The firm has a market capitalization of $6.58 billion, a PE ratio of 24.36 and a beta of -0.03. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.86.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter in the previous year, the firm posted $1.53 EPS. Lantheus’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts forecast that Lantheus will post 4.5 EPS for the current year.

Institutional Investors Weigh In On Lantheus

Large investors have recently bought and sold shares of the company. Western Wealth Management LLC bought a new position in Lantheus in the 1st quarter valued at about $25,000. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus during the 2nd quarter worth approximately $36,000. Smartleaf Asset Management LLC boosted its position in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares in the last quarter. Bessemer Group Inc. boosted its position in shares of Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 354 shares in the last quarter. Finally, Parallel Advisors LLC increased its stake in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 298 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Curium agreed to acquire Lantheus for $102.50 per share in cash, with non-transferable contingent value rights (CVRs) offering up to an additional $12 per share if specified prostate-cancer, neurology and DEFINITY sales milestones are achieved through 2030. The total potential value is approximately $8 billion. Reuters article
• Positive Sentiment: The deal represents premiums to Lantheus’ unaffected trading levels, and the company’s board unanimously approved it after reviewing multiple strategic alternatives, including remaining independent. The combination would unite Lantheus’ U.S. radiodiagnostics business with Curium’s global manufacturing and theranostics platform across more than 70 countries. Curium Announces Definitive Agreement to Merge with Lantheus
• Positive Sentiment: Analyst commentary highlighted the transaction as a favorable outcome for shareholders, while recent reported price targets—including a median target of $115—remain above the cash consideration, potentially reflecting value in the CVRs. Analyst insights on Lantheus
• Neutral Sentiment: The transaction is expected to close in the first half of 2027, subject to shareholder and regulatory approvals. Until then, Lantheus will remain publicly traded; afterward, it will become private. Fierce Biotech article
• Neutral Sentiment: Analyst sentiment is mixed, suggesting limited independent-stock catalysts while the acquisition is pending. Lantheus is scheduled to report second-quarter 2026 results before the market opens on August 6, but it will not hold a conference call. Conflicting analyst sentiment on Lantheus
• Negative Sentiment: Lantheus suspended its previously issued FY 2026 guidance because of the pending transaction, increasing uncertainty around near-term operating performance and limiting visibility for standalone valuation.
• Negative Sentiment: Several shareholder law firms announced investigations into whether Lantheus obtained a fair price and whether directors fulfilled their fiduciary duties. Such actions could raise legal costs or delay closing, although they do not necessarily indicate wrongdoing. Shareholder investigation
• Negative Sentiment: The additional $12 per share is contingent on demanding commercial milestones and is not guaranteed. Investors also face normal merger risks, including financing, regulatory approval, shareholder approval and potential competing bids.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.